SAFETY DATA SHEETS

This SDS packet was issued with item:

078916936

N/A

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 1 of 22



SECTION 1: IDENTIFICATION							
1.1 Product identifier							
Product name:	Osphos® (60 mg/ml Solution for Injection)						
Synonyms:	lot Available						
Proper Shipping name:	Not applicable						
Other means of identification:	None						
1.2 Relevant identified uses	of the substances or mixture and uses advised against						
Recommended uses:	Solution for injection for the control of clinical signs associated with the bone resorptive processes of navicular syndrome in horses.						
Uses advised against:	Not for human use. Not to be used in horses intended for human consumption. Treated horses may never be slaughtered for human consumption.						
1.3 Details of the supplier o	f the substance or mixture						
Registered company name (UK):	Dechra Ltd						
Address:	Snaygill Industrial Estate Keighley Road Skipton North Yorkshire BD23 2RW UK						
Telephone:	+44 (0) 1756 791311						
Fax:	+44 (0) 1756 798604						
Website:	www.dechra.com						
Email:	Not available						
Registered company name (US):	Dechra Veterinary Products						
Address:	Dechra Pharmaceutical Products 7015 College Blvd Suite 525 Overland Park KS 66211 USA						
Telephone:	866-933-2472						
Fax:	Not available						

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 2 of 22



Website:	www.dechra.com							
Email:	Not available							
1.4 Emergency Telephone Numbers								
Dechra (US):	866-933-2472							

SECTION 2: HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

Considered a hazardous mixture according to Reg. (EC) No 1272/2008 and their amendments. Not classified as Dangerous Goods for transport purposes (EU).

Considered a Hazardous Substance by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200). Not classified as Dangerous Goods for transport purposes (US).

In case of mixtures, classification has been prepared by following DPD (Directive 1999/45/EC) and CLP Regulation (EC) No 1272/2008 regulations						
R63(3): Possible risk of harm to the unborn child						
Classified by Chemwatch						
H361: Reproductive Toxicity Category 2						
Classified by Chemwatch						
Eye Irritation Category 2B, Reproductive Toxicity Category 2						

2.2 Label Elements

GHS Label Elements:



Signal Word: WARNING

Hazard statement(s):

H303 May be harmful if swallowed.

H320 Causes eye irritation.

H361 Suspected of damaging fertility or the unborn child.

Precautionary Statement(s) Prevention:

P201 Obtain special instructions before use.

P264 Wash all exposed external body areas thoroughly after handling.

P281 Use personal protective equipment as required.

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 3 of 22



Precautionary Statement(s) Response:							
P312 Call a POISON CENTER or doctor/physician if you feel unv							
P308 + P313 IF exposed or concerned: Get medical advice/attention.							
P337 + P313 If eye irritation persists: Get medical advice/attention.							
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.						
Precautionary Statement(s)	Storage:						
P405 Store locked up.							
Precautionary Statement(s) Disposal:							
P501 Dispose of contents/container in accordance with local regulations.							
II							

2.3 Other Hazard Information

Ingestion may produce health damage*
Cumulative effects may result following exposure*
May produce discomfort of the eyes*

REACH (EU) Article 57-59: The mixture does not contain Substances of Very High Concern (SVHC) at the SDS print date.

SECTION 3: INFORMATION ON THE INGREDIENTS

3.1 Substances

See section below for composition of mixtures

3.2 Mixtures

1.CAS No 2.EC Number 3.Index Number 4.REACH Number	% Weight	Name	Classification according to directive 67/548/EEC [DSD] (EU)	Classification according to regulations (EC) No 1272/2008 [CLP] (EU)		
1. 22560-50-5 2. 245-078-9 3. Not Available 4. Not Available	6	Clodronic Acid (51mg/ml) as Disodium Clodronate (60mg/ml)	R53, R63(3) ¹	Reproductive Toxicity Category 2, Chronic Aquatic Hazard Category 4; H361, H413 ¹		
1. 1310-73-2 2. 215-185-5 3. 011-002-00-6 4. 01-2119457892- 27-XXXX,	<0.1	Sodium Hydroxide	R35 ²	Skin Corrosion/Irritation Category 1A; H314 ³		

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 4 of 22



01-2119982981-22- XXXX							
Legend:	1. Classified by Chemwatch; 2. Classification drawn from EC Directive 67/548/EEC - Annex I; 3. Classification drawn from EC Directive 1272/2008 – Annex VI						

SECTION 4: FIRST AID MEASURES						
4.1 Description of first a	aid measures					
Eye contact:	Accidental spillage on the eyes should be washed off with plenty of water. If pain or irritation occurs, seek medical advice and show the package leaflet or the label to the medical practitioner.					
Skin contact:	Accidental spillage on the skin should be washed off with plenty of water. If irritation occurs, seek medical advice and show the package leaflet or the label to the medical practitioner.					
Inhalation:	Inhalation is highly unlikely due to the nature of the product and how it is packaged and administered. If irritation or difficulty in breathing occurs, seek urgent medical advice and show the package leaflet or the label to the medical practitioner. Remove the patient from the contaminated area. Lay the patient down, keep warm and rested.					
Ingestion:	Ingestion is highly unlikely due to the nature of the product and how it is packaged and administered. If swallowed, seek urgent medical advice and show the package leaflet or the label to the medical practitioner. Remove material and give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink.					
Self-injection:	Care should be taken when handling the product to avoid self-injection, especially by pregnant women. Read the package leaflet before use for full instructions and user warnings.					
4.2 Most important symptoms and effects, both acute and delayed						
See Section 11						
4.3 Indication of immediate medical attention and special treatment needed Not applicable						

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 5 of 22



SECTION 5: FIRE FIGHTING MEASURES							
5.1 Extinguishing media							
Suitable:	Select extinguishing media suitable for surrounding area						
Unsuitable:	There is no restriction on the type of extinguisher which may be used						
5.2 Special hazards arisir	ng from the substance or mixture						
Fire incompatibility:	None known						
5.3 Special protective act	5.3 Special protective actions for fire-fighters:						
Firefighting:	Wear breathing apparatus plus protective gloves in the event of a fire. Prevent, by any means available, spillage from entering drains or water courses DO NOT approach containers suspected to be hot. Equipment should be thoroughly decontaminated after use.						
Fire / explosion hazard:	Non-combustible. Not considered a significant fire risk, however containers may burn. May emit poisonous fumes. May emit corrosive fumes.						

may offic corrective families.						
SECTION 6: ACCIDENTAL RELEASE MEASURES						
6.1 Personal precautions, protective equipment and emergency procedures						
For information on pr	otective equipment, see section 8					
6.2 Environmental	Precautions					
See sect	ion 12					
	6.3 Methods and material for containment and cleaning up Spills are unlikely due to the nature of the product and how it is packaged					
Minor Spills: Clean up all spills immediately. Avoid breathing vapours and contact with skin and eyes. Control personal contact with the substance, by using protective equipment. Contain and absorb spill with sand, earth, inert material or vermiculite Place in a suitable, labelled container for waste disposal.						
Major Spills:	Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of the hazard. Contain and absorb spill with sand, earth, inert material or vermiculite. Prevent, by any means available, spillage from entering drains or water					

course.

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 6 of 22



SECTION 7: HANDLING AND STORAGE								
7.1 Precautions for safe h	7.1 Precautions for safe handling							
Safe Handling:	Wear suitable protection gloves and clothing when handling the product. When handling, DO NOT eat, drink or smoke. Always wash hands with water after handling. In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician. Observe manufacturer's storage and handling recommendations.							
Other Information:	Do not store above 25°C. Discard unused material. Keep out of the reach and sight of children.							
7.2 Conditions for safe sto	orage, including any incompatibilities							
Suitable Container:	Keep the container in the outer carton. Check that containers are clearly labelled. Once broached use immediately. The diluted infusion solution may be stored for up to 24 hours at room temperature. Shelf life of the veterinary medicinal product as packaged for sale: 2 years.							
Storage incompatibility:	No known incompatibilities.							
7.3 Specific end uses								
Not available								

SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION
8.1 Control parameters
DERIVED NO EFFECT LEVEL - DNEL (EU)
Not Available
PREDICTED NO EFFECT LEVEL - PNEC (EU)
Not Available
OCCUPATIONAL EXPOSURE LIMITS (OEL)

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 7 of 22



INGREDIENT DATA (EU):												
Source	Ingred	3		terial TWA me		STEL		Peak		Notes		
UK Workplace Exposure Limits (WELs)			Sodium Hydroxide		Not Available	2 mg/m ³		Not Available		Not Available		
INGREDIENT D	INGREDIENT DATA (US):											
Source	5		Material Name		TWA	STEL		Peak		Notes		
US OSHA Permissible Exposure Levels (PELs) - Table Z1				n kide	2 mg/m3		Not Available		Not Available		Not Available	
US ACGIH Threshold Limit Values (TLV)	Sodiur Hydrox				Not Available	Not Available Availabl		е	2 mg/m3		TLV® Basis: URT, eye, & skin irritation	
US NIOSH Recommended Exposure Limits (RELs)	Sodiur Hydrox			_ye, ye, n	Not Available		Not Available		2 mg/m3		Not Available	
EMERGENCY L	IMITS (EU/US	s):									
Ingredient		Mater Name	-		TEEL-2		TEE		L-3			
Sodium Hydroxid	de	Sodiu Hydro			Available	Not Available		Not Available				
Ingredient			Origi	Original IDLH				Revised IDLH		LH	.Н	
Clodronic acid (Disodium Clodronate)		Not A	Not Available				Not Available					
Sodium Hydroxide			250 m	250 mg/m ³			10 mg/m ³					
Water			Not Available Not Available									
8.2 Exposure c	ontrols	i										
Appropriate engineering controls: controls: The basic types of engineering controls are: Process controls which involve changing the way a job activity or process is done to reduce the particular risk												

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 8 of 22



Personal protection:			
Eye and face protection:	Safety glasses with side shields / chemical goggles		
Skin protection:	See hand protection below		
Hands/ feet protection:	No special equipment needed when handling small quantities. OTHERWISE: Wear chemical protective gloves		
Body protection:	Wear appropriate clothing		
Other protection:	No special equipment needed when handling small quantities		
Thermal hazards:	Not applicable		
Respiratory protection:	Not applicable		
8.3 Environmental exposure co See Section 12	ontrols		

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 9 of 22



SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance: Osphos: Clear and colourless aqueous solution

Clodronic acid (Disodium Clodronate): White crystalline powder

Container: cardboard carton containing a clear 15ml Type I glass vial with a grey siliconised

rubber stopper and aluminium seal.

Physical state: Liquid Odour: Not available

Odour Threshold: Not available pH (as supplied): 3.8 – 4.5

Melting point / freezing point (degrees C): Not available **Initial boiling point and boiling range:** Not available

Flash Point: In water – no flash point Evaporation rate: Not available Flammability: Not available

Upper/lower flammability or explosive limits: Not available

Vapour pressure: Not available

Relative Density (at degrees C): Not available

Solubility in water and solvents (mg/l): Freely soluble (water)

Chloroform – Practically insoluble Benzene – Practically insoluble Ethylether – Practically insoluble

Vapour density: Not available

Auto ignition temperature (degrees C): Not available Decomposition temperature (degrees C): Not available

Viscosity: (degrees C): Not available Explosive properties: Not available Oxidising properties: Not available Partition Coefficient: Not available

Molecular weight: Disodium Clodronate: 360.93 (anhydrous: 288.9)

Taste: Not available

Surface tension: Not available **Volative component:** Not available

Gas group: Not available pH as a solution: Not available

VOC g/L: Not available

9.2 Other information

Not Available

10: REACTIVITY AND STABILITY		
10.1 Reactivity:	See Section 7	
10.2 Chemical stability:	Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur.	
10.3 Possibility of	The product is not considered to be hazardous if used as per	

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 10 of 22



hazardous reactions:	instructions. Hazardous polymerisation will not occur.
10.4 Conditions to avoid:	See Section 7.
10.5 Incompatible materials:	See section 7.
10.6 Hazardous decomposition:	See Section 5.

SECTION 11: TOXICOL	OGICAL INFORMATION		
Inhalation:	The material can cause respiratory irritation in some persons.		
Ingestion:	Accidental ingestion of the months of the individual.	aterial may be damaging to the health	
Skin contact:	The material is not thought to produce adverse health effects or skin irritation following contact (as classified by EC Directives using animal models). The acids and salts of ATMP, HEDP and DTPMP have a low level of acute skin toxicity. ATMP acid and its salts, in testing, were found to be practically non-toxic.		
Eye contact:	Can cause eye irritation in some persons. The phosphonic acid compounds, ATMP, HEDP, DTPMP and their salts vary in their potential to irritate the eye, from virtually non-irritating to severely irritating with irreversible effects.		
Chronic:	Substance accumulation, in the human body, may occur and may cause some concern following repeated or long-term occupational exposure. Exposure to small quantities may induce hypersensitivity reactions characterised by acute bronchospasm, hives (urticaria), deep dermal wheals (angioneurotic oedema), running nose (rhinitis) and blurred vision. Anaphylactic shock and skin rash (nonthrombocytopenic purpura) may occur.		
Self-injection:	The most common adverse effects include gastrointestinal disturbances. In general, clodronate is well tolerated following intravenous, intramuscular or oral administration.		
Osphos:	Toxicity	Irritation	
	Not Available	Not Available	

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017 Version No: 1 Page 11 of 22



SECTION 11: TOXICOL	OGICAL INFORMATION	
Clodronic acid	Acute toxicity	Irritation
(Disodium Clodronate):	Oral (mouse) LD ₅₀ : >2000 mg/kg ² The most common adverse effects include gastrointestinal disturbances, including nausea, and vomiting and diarrhoea, following oral administration of clodronate which can be alleviated by dividing or lowering the dosage. In most cases, these effects are mild and transient. In general, clodronate is well tolerated following intravenous, intramuscular or oral administration.	Not available
Sodium Hydroxide:	Toxicity	Irritation
	Oral (rabbit) LD ₅₀ : 325 mg/kg ¹	Eye (rabbit): 0.05 mg/24h SEVERE Eye (rabbit):1 mg/24h SEVERE Eye (rabbit):1 mg/30s rinsed-SEVERE Skin (rabbit): 500 mg/24h SEVERE
Water:	Toxicity	Irritation
	Oral (rat) LD ₅₀ : >90000 mg/kg ²	Not Available

^{1.} Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's SDS. Unless otherwise specified, data extracted from RTECS - Register of Toxic Effect of chemical Substances

Skin corrosion/ irritation:

Not Available

Serious eye damage/ irritation:

Sodium Hydroxide may produce severe irritation to the eye causing pronounced inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis.

Respiratory or skin sensitization:

Not Available

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017 Version No: 1 Page 12 of 22



SECTION 11: TOXICOLOGICAL INFORMATION
Germ cell mutagenicity:
Not Available
Carcinogenicity:
Not Available
Reproductive toxicity:
In rat studies, Disodium Clodronate is shown to have detrimental effects during pregnancy.
STOT – single exposure:
Not Available
STOT-repeated exposure:
Not Available
Aspiration hazard:

SECTION 12: ECOLOGICAL INFORMATION

12.1 Toxicity

Not Available

Ingredient	Endpoint	Test duration (hr)	Species	Value	Source
Sodium Hydroxide	LC ₅₀	96	Fish	4.16158mg/L	1
Sodium Hydroxide	EC ₅₀	96	Algae or other aquatic plants	1034.10043mg/L	1
Sodium Hydroxide	EC ₅₀	384	Crustacea	27901.643mg/L	1
Sodium Hydroxide	NOEC	96	Fish	56mg/L	2
			4 5504/44 6 1/ 1	(0.40.(0045) 4	(· + · · ·

Legend: 1. EPIWIN Suite V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 2. US EPA, Ecotox database - Aquatic Toxicity Data

DO NOT discharge into sewer or waterways.

12.2 Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
Sodium Hydroxide	LOW	LOW
Water	LOW	LOW
40.0 5:		

12.3 Bioaccumulative potential

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 13 of 22



Ingredient	Bioaccumulative Potential		
Sodium Hydroxide	LOW (LogKOW = -3.8796)		
Water	LOW (LogKOW = -1.38)		
12.4 Mobility in So	il		
Ingredient	Mobility		
Sodium Hydroxide	LOW (KOC = 14.3)		
Water	LOW (KOC = 14.3)		
12.5 Results of PB Not Applicable	T and vPvB assessment		
12.6 Other adverse Not Available	12.6 Other adverse effects Not Available		

SECTION 13: DISP	SECTION 13: DISPOSAL CONSIDERATIONS		
13.1 Waste treatm	ent methods		
packaging	Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with national requirements.		
	Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. A Hierarchy of Controls seems to be common - the user should investigate: Reduction Reuse Recycling Disposal (if all else fails) Ensure that the disposal of material is carried out in accordance with Hazardous Substances (Disposal) Regulations 2001.		
Waste Treatment Options:	Not Available		
Sewage Disposal Options:	Not Available		

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017 Version No: 1 Page 14 of 22



SECTION 14: TRANS	PORT INFORMATION			
Labels required:				
Marine pollutant:	NO	NO		
Hazchem:	Not Applicable			
Land transport (EU: DANGEROUS GOOD		REGULATED FOR TRANSPORT OF		
14.1 UN Number	N/a			
14.2 UN Proper Shipping Name	N/a			
14.3 Transport	Class	N/a		
hazard class(es)	Sub risk	N/a		
14.4 Packing group	N/a			
14.5 Environmental hazards	N/a			
14.6 Special precautions for	Special provisions	N/a		
user	Limited quantity	N/a		
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a			
Air transport (ICAO-IDANGEROUS GOOD		ULATED FOR TRANSPORT OF		
14.1 UN Number	N/a			
14.2 UN Proper Shipping Name	N/a			
14.3 Transport	ICAO/IATA Class	N/a		
hazard class(es)	ICAO / IATA Sub risk	N/a		
	ERG Code	N/a		
14.4 Packing group	N/a			
14.5 Environmental hazards	N/a			
	Special provisions	N/a		
precautions for user	Cargo only packing instructions	N/a		

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017 Version No: 1 Page 15 of 22



	Cargo only maximun qty/pack	n N/a	
	Passenger and cargo packaging instruction		
	Passenger and cargo maximum qty/pack	N/a	
	Passenger and cargilimited quantity packing instructions	N/a	
	Passenger and cargo limited maximum qty/pack	N/a	
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a		
Sea transport (IMDG DANGEROUS GOOD		OT REGULATED FOR TRANSPORT OF	
14.1 UN Number	N/a		
14.2 UN Proper Shipping Name	N/a		
14.3 Transport	IMDG Class	N/a	
hazard class(es)	IMDG Sub risk	N/a	
14.4 Packing group	N/a		
14.5 Environmental hazards	N/a		
-	EMS Number	N/a	
precautions for user	Special provisions	N/a	
	Limited quantities	N/a	
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a		
Inland waterways tra	neport (ADN): NOT	REGULATED FOR TRANSPORT OF	

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017 Version No: 1 Page 16 of 22



14.1 UN Number	N/a	
14.2 UN Proper Shipping Name	N/a	
14.3 Transport hazard class(es)	N/a N/a	
14.4 Packing group	N/a	
14.5 Environmental hazard	N/a	
	Classification Code	N/a
precautions for user	Special provisions	N/a
	Limited quantity	N/a
	Equipment required	N/a
	Fire cones number	N/a
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a	

SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations / legislation specific for the substance or mixture

CLODRONIC ACID (DISODIUM CLODRONATE) (22560-50-5) IS FOUND ON THE FOLLOWING REGULATORY LISTS:

European Union - European Inventory of Existing Commercial Chemical Substances (EINECS) (English)

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 17 of 22



SODIUM HYDROXIDE (1310-73-2) IS FOUND ON THE FOLLOWING REGULATORY LISTS:

- European Customs Inventory of Chemical Substances ECICS (English)
- European Union European Inventory of Existing Commercial Chemical Substances (EINECS) (English)
- European Union (EU) Annex I to Directive 67/548/EEC on Classification and Labelling of Dangerous Substances updated by ATP: 31
- European Union (EU) Regulation (EC) No 1272/2008 on Classification, Labelling and Packaging of Substances and Mixtures Annex VI
 - UK Workplace Exposure Limits (WELs)
 - US Alaska Limits for Air Contaminants
 - US California OEHHA/ARB Acute Reference Exposure Levels and Target Organs (RELs)
 - US California Permissible Exposure Limits for Chemical Contaminants
 - US Hawaii Air Contaminant Limits
 - US Idaho Limits for Air Contaminants
 - US Massachusetts Right To Know Listed Chemicals
 - US Michigan Exposure Limits for Air Contaminants
 - US Minnesota Permissible Exposure Limits (PELs)
 - US Oregon Permissible Exposure Limits (Z-1)
 - US Pennsylvania Hazardous Substance List
 - US Rhode Island Hazardous Substance List
 - US Tennessee Occupational Exposure Limits Limits For Air Contaminants
 - US Vermont Permissible Exposure Limits Table Z-1-A Final Rule Limits for Air Contaminants
 - US Vermont Permissible Exposure Limits Table Z-1-A Transitional Limits for Air Contaminants
 - US Washington Permissible exposure limits of air contaminants
 - US Washington Toxic air pollutants and their ASIL, SQER and de minimis emission values
 - US Wyoming Toxic and Hazardous Substances Table Z1 Limits for Air Contaminants
 - US ACGIH Threshold Limit Values (TLV)
 - US CWA (Clean Water Act) List of Hazardous Substances
 - US NIOSH Recommended Exposure Limits (RELs)
 - US OSHA Permissible Exposure Levels (PELs) Table Z1
 - US Toxic Substances Control Act (TSCA) Chemical Substance Inventory

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 18 of 22



This safety data sheet is in compliance with the following EU legislation and its adaptations - as far as applicable: 98/24/EC, 92/85/EC, 94/33/EC, 91/689/EEC, 1999/13/EC, Commission Regulation (EU) 2015/830, Regulation (EC) No 1272/2008 and their amendments.

FEDERAL REGULATIONS:

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Section 311/312 Hazard Categories

Immediate (acute) health hazard	Yes
Delayed (chronic) health hazard	Yes
Fire hazard	No
Pressure hazard	No
Reactivity hazard	No

US. EPA Cercla Hazardous Substances and Reportable Quantities (40 CFR 302.4)

	Reportable Quantity in Pounds (lb)	Reportable Quantity in kg
Sodium hydroxide	1000	454

STATE REGULATIONS:

US. CALIFORNIA PROPOSITION 65

None reported

15.2 Chemical Safety Assessment

ECHA SUMMARY

Ingredient	CAS number	Index Number	ECHA Dossier
Clodronic acid (Disodium Clodronate)	22560-50-5	Not Available	Not Available

Harmonization (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	STOT RE 2, Aquatic Chronic 2	GHS09, GHS08, Wng	H373
2	STOT RE 2, Aquatic Chronic 2	GHS09, GHS08, Wng	H373
1	Acute Tox. 4, Repr. 2, Aquatic Chronic 3	GHS07, GHS08, Wng	H302, H332, H361
2	Acute Tox. 4, Repr. 2, Aquatic Chronic 3	GHS08, Wng	H302, H332, H361

Harmonization Code 1 = The most prevalent classification. Harmonization Code 2 = The most severe classification

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 19 of 22



Ingredient	CAS Number	Index Number	ECHA Dossier
Sodium Hydroxide	1310-73-2		01-2119457892-27- XXXX, 01-2119982981- 22-XXXX

Harmonization (C&L Inventory)	Hazard Class and Category Code(s)	Index Number	ECHA Dossier
1	Skin Corr. 1A	GHS05, Dgr	H314
2	Skin Corr. 1A	GHS05, Dgr	H314
1	Skin Corr. 1A	GHS05, Dgr	H314
2	Met. Corr. 1, Skin Corr. 1A, Eye Dam. 1, Acute Tox. 4, Skin Corr. 1B, STOT SE 3, Eye Irrit. 2, Aquatic Chronic 3, STOT SE 1, Skin Corr. 1C, Aquatic Acute 3	GHS05, Dgr, GHS06, GHS08	H290, H314, H312, H318, H335, H370, H302
1	Skin Corr. 1A	GHS05, Dgr	H314
2	Skin Corr. 1A	GHS05, Dgr	H314, H302

Harmonization Code 1 = The most prevalent classification. Harmonization Code 2 = The most severe classification

Ingredient	CAS Number	Index Number	ECHA Dossier
Water	7732-18-5	Not Available	Not Available

Harmonization (C&L Inventory)		Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Not Classified	GHS06, GHS05, Dgr, GHS02, Wng	H301, H226, H314
2	T	GHS06, GHS05, Dgr, GHS02, Wng	H301, H226, H314

Harmonization Code 1 = The most prevalent classification. Harmonization Code 2 = The most severe classification

National Inventory	Status
Australia - AICS	N (clodronic acid, sodium salt)
Canada - DSL	N (clodronic acid, sodium salt)

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 20 of 22



Canada - NDSL	N (clodronic acid, sodium salt, water, sodium hydroxide)
China - IECSC	N (clodronic acid, sodium salt)
Europe - EINEC / ELINCS / NLP	Υ
Japan - ENCS	N (clodronic acid, sodium salt, water)
Korea - KECI	N (clodronic acid, sodium salt)
New Zealand - NZIoC	N (clodronic acid, sodium salt)
Philippines - PICCS	N (clodronic acid, sodium salt)
USA - TSCA	N (clodronic acid, sodium salt)
Legend:	Y = All ingredients are on the inventory N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)

SECTION 16: OTHER INFORMATION

The SDS is written in accordance to guidelines specified by REACH, GHS, OSHA and ECHA.

Full text Risk and Hazard codes:

H226	Flammable liquid and vapour
H290	May be corrosive to metals
H301	Toxic if swallowed
H302	Harmful if swallowed
H312	Harmful in contact with skin
H314	Causes severe skin burns and eye damage
H318	Causes serious eye damage
H332	Harmful if inhaled
H335	May cause respiratory irritation
H370	Causes damage to organs
H373	May cause damage to organs through prolonged or repeated exposure
H413	May cause long lasting harmful effects to aquatic life

R35	Causes severe burns
R53	May cause long-term adverse effects in the aquatic environment

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 21 of 22



Ingredients with multiple CAS numbers:

Name	CAS Number
Clodronic acid (Disodium Clodronate)	22560-50-5, 88416-50-6
Sodium Hydroxide	1310-73-2, 12200-64-5

Relevant risk statements are found in section 2.1

|--|

S02	Keep out of reach of children
S23	Do not breate gas/fumes/vapour/spray
S35	This material and its container must be disposed of in a safe way
S36	Wear suitable protective clothing
S37	Wear suitable gloves
S40	To clean the floor and all objects contaminated by this material, use water and
	detergent
S46	If swallowed, seek medical advice immediately and show this container or label
S53	Avoid exposure – obtain special instructions before use
S56	Dispose of this material and its container at hazardous or special waste collection
	point

For detailed advice on Personal Protective Equipment, refer to the following EU CEN Standards:

EN 166 Personal eye-protection

EN 340 Protective clothing

EN 374 Protective gloves against chemicals and micro-organisms

EN 13832 Footwear protecting against chemicals

EN 133 Respiratory protective devices

NFPA 704 diamond (US):



Blue = Health, Red = Fire, Yellow = Reactivity, White = Special (Oxidizer or water reactive substances)

Product Name: Osphos® (60mg/ml Solution for Injection)

Issue Date: 09/2017

Version No: 1 Page 22 of 22



Definitions and abbreviations

PC—TWA: Permissible Concentration-Time Weighted Average PC—STEL: Permissible Concentration-Short Term Exposure Limit

STEL: Short Term Exposure Limit

TEEL: Temporary Emergency Exposure Limit

IDLH: Immediately Dangerous to Life or Health Concentrations

The information provided in this Safety Data Sheet has been compiled by Dechra Limited using a number of different sources, and is correct to the best of its knowledge, information and belief as at the date of its publication. However, Dechra Limited makes no warranties, express or implied, in relation to the information set out in this Safety Data Sheet, including, without limitation, as to its accuracy or completeness.

The information provided is not a quality specification, and is prepared by way of guidance as to the safe handling, use, processing, storage, transportation, disposal and release of the relevant products referred to. The user is responsible for determining whether or not the product is fit for any particular purpose and/or suitable for the user's proposed method of use and application.

Copyright, 2017, Dechra Limited. All rights reserved.

Copying and/or downloading of this information for the purpose of properly utilizing Dechra Limited products is permitted provided that: (1) the information is copied in full with no changes unless prior written agreement is obtained from Dechra Limited, and (2) neither the copy nor the original is resold or otherwise distributed for the purposes of making a profit thereon.